ONCOBELL 2nd INTERNATIONAL SYMPOSIUM
«Building bridges between science, cancer medicine and persons»
Barcelona, September 19-20th, 2022. Auditorium, Bellvitge University Hospital.
0000
08.00h – 08.30h
REGISTRATION
08.30h – 09.00h
WELCOME
09.00h – 10.00h
OPENING KEYNOTE LECTURE
Imaging and targeting of premetastatic niches in melanoma. Marisol Soengas, CNIO, Madrid,
10.00h – 12.00h
SESSION 1: IMMUNE SYSTEM, INFLAMMATION AND CANCER
Chaired by: Ramón Alemany, Oncobell Program, IDIBELL – ICO.
CD137-based immunotherapy from bench to bed and back to the future. Ignacio Melero, Clínica Universitaria de Navarra, Navarra.
Developing immunotherapeutic strategies in rare tumors: Uveal melanoma as an example. Josep Maria Piulats, Oncobell Program, IDIBELL – ICO.
Role of the ecosystem in hepatobiliary cancer progression. Gianluigi Giannelli, GG National Institute of Gastroenterology Saverio De Bellis, Castellana Grotte, Bari, Italy.
Protumorogenic consequences of starvation in the tumor microenvironment. Cristina Muñoz-Pinedo, Oncobell Program, IDIBELL- UB.
12.00h – 12.30h
COFFE BREAK
12.30h – 13.30h
ROUND TABLE: CLINICAL INNOVATION: TECHNOLOGY AND MANAGEMENT
Chaired by: Ferran Guedea, Oncobell Program, IDIBELL – ICO & Jordi Ponce, Oncobell Program, IDIBELL- HUB..
Radiation with proton and FLASH therapy. Jean Bourhis, CHUV, Lausanne, Switzerland
Technological and process innovation. Robotics and enhanced recovery after surgery (ERAS). Jordi Ponce, Oncobell Program, IDIBELL- HUB
Digital Pathology as a tool to improvepathology workload, diagnosis and research. The example of DigiPATcs. Xavier Matias-Guiu, Oncobell Program, IDIBELL – HUB.
13.30h – 16.00h
POSTER SESSION & LUNCH
14:30 – 15:15 Even-numbered posters
15:15 – 16:00 Odd-numbered posters
16.00h – 18.00h
SESSION 2: DNA REPAIR AND GENOMICS IN CANCER
Chaired by: Barbara Rivera, Oncobell Program, IDIBELL- ICO.
The chronic lymphocytic leukemia epigenome: biological insights and clinical applications. Iñaki Martín Subero, IDIBAPS, Barcelona.
Latest insights into colorectal cancer predisposition. Laura Valle, Oncobell Program, IDIBELL- ICO.
Understanding oncogenesis across biological scales: from individual mutations to tissue structure. Eduard Porta, BSC, Barcelona.
Clinical implications of DNA repair defects in prostate cancer. Elena Castro, Hospital 12 de Octubre, Madrid, Spain
0000
08.30h – 10.30h
SESSION 3: TARGETING SIGNALING PATHWAYS
Chaired by: Purificación Muñoz, Oncobell Program, IDIBELL.
Inflammation and ER stress pave the way to pancreatic cancer. Francisco X. Real, CNIO, Madrid, Spain.
Identification of new oncogenic drivers involved in GTPase signaling. Xosé R. Bustelo, CSIC, Universidad de Salamanca.
Understanding chemotherapy resistance in T cell Acute lymphoblastic leukemia. Anna Bigas, IMIM, Barcelona, Spain.
Predictive Power of TGF-β Signaling in Cancer Therapy. Mary Helen Barcellos-Hoff, University of California, (UCSF), USA.
10.30h – 11.00h
COFFE BREAK
11.00h – 13.00h
SESSION 4: METASTASIS & RESPONSE TO THERAPY
Chaired by: Isabel Fabregat, Oncobell Program, IDIBELL – UB – CIBERehd.
Stem cell-like immunotherapy resistance in metastatic breast cancer. Antoni Celià Terrassa, IMIM, Barcelona, Spain.
Ovarian cancer dissemination relies on PDGFRs and S1PR1 for tumorsphere formation and proliferation. Francesc Viñals, Oncobell Program, IDIBELL -UB- ICO,
Breast Cancer metastasis cell fate. Roger Gomis, IRB, Barcelona,
The amoeboid state as part of the epithelial to mesenchymal transition program in cancer. Vicky Sanz Moreno, Barts Cancer Institute, QMUL, London, UK.
13.00h – 14.00h
CLOSING KEYNOTE LECTURE
Exploiting immune surveillance to target colorectal cancer evolution and mutability. Alberto Bardelli, IFOM, ETS, Milan and University of Torino, Dept. of Oncology, Italy.
14.00h – 14.15h
CLOSING SESSION
0000